Summary & Overview
CPT 81478: Genetic Testing for CYP2C19 Drug Metabolism
CPT code 81478 represents genetic analysis of the CYP2C19 gene, a key enzyme involved in drug metabolism. This test identifies common genetic variants that can influence how patients process medications, impacting treatment decisions across a range of clinical scenarios including cardiovascular disease and mental health. The code is widely recognized in medical genetics and pathology, and is typically performed in laboratory settings.
Blue Cross Blue Shield is a primary payer covered in this analysis. Readers will gain insight into payer coverage, relevant clinical indications, and associated billing practices for genetic testing services. The publication also highlights related CPT codes for other cytochrome P450 gene analyses, common modifiers used in laboratory billing, and the clinical context for ordering CYP2C19 testing. Benchmarks and policy updates are provided to inform stakeholders about current trends in genetic testing reimbursement and utilization.
This summary offers a comprehensive overview of CPT code 81478, including its clinical significance, payer landscape, and billing considerations. Healthcare professionals, laboratory administrators, and policy analysts will find actionable information to support decision-making in genetic testing services.
CPT Code Overview
CPT code 81478 is used for genetic testing of the CYP2C19 gene, which plays a critical role in drug metabolism. This test analyzes common variants such as *2, *3, *4, *8, and *17 to help determine how a patient may respond to certain medications. The service type is genetic testing, and it is typically performed in a laboratory setting (POS 81). This testing provides valuable information for clinicians to tailor drug therapy based on individual genetic profiles.
Clinical & Coding Specifications
Clinical Context
A patient is referred for genetic testing to evaluate their CYP2C19 gene variants, which influence drug metabolism. This is commonly performed in a laboratory (POS 81) setting. The test is ordered when a patient is being considered for medications metabolized by CYP2C19, such as certain antiplatelet drugs or antidepressants. The workflow involves the provider collecting a specimen, sending it to a laboratory specializing in molecular genetics, and receiving a report detailing the patient's CYP2C19 genotype. This information assists in tailoring drug therapy based on the patient's genetic profile.
Coding Specifications
-
Modifiers:
-
Modifier
26: Indicates the professional component of the laboratory service, typically used when the interpretation of the genetic test is performed by a qualified provider. -
Modifier
91: Used when the laboratory test is repeated for the same patient, such as monitoring changes or confirming previous results.
-
-
Provider Taxonomies:
| Taxonomy Code | Specialty Name |
|---|